Yu T. Qian

Qingchun Road 79#
Hangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

m6A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia.

m6A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia.

Journal: Clinical and translational medicine

Published: October 22, 2023

Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML.

Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML.

Journal: Biomarker research

Published: August 06, 2023

CPT1B, a metabolic molecule, is also an independent risk factor in CN-AML.

CPT1B, a metabolic molecule, is also an independent risk factor in CN-AML.

Journal: Cancer biomarkers : section A of Disease markers

Published: March 20, 2023

Glutamate dehydrogenase 1: A novel metabolic target in inhibiting acute myeloid leukaemia progression.

Glutamate dehydrogenase 1: A novel metabolic target in inhibiting acute myeloid leukaemia progression.

Journal: British journal of haematology

Published: February 27, 2023

A cell-level discriminative neural network model for diagnosis of blood cancers.

A cell-level discriminative neural network model for diagnosis of blood cancers.

Journal: medRxiv : the preprint server for health sciences

Published: February 17, 2023

circSLC25A13 acts as a ceRNA to regulate AML progression via miR-616-3p/ADCY2 axis.

circSLC25A13 acts as a ceRNA to regulate AML progression via miR-616-3p/ADCY2 axis.

Journal: Molecular carcinogenesis

Published: January 31, 2023

Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2/STAT3/STAT5 axis.

Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2/STAT3/STAT5 axis.

Journal: Journal of translational medicine

Published: November 11, 2022

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.

Journal: Molecular oncology

Published: July 21, 2022

FLOT1 knockdown inhibits growth of AML cells through triggering apoptosis and pyroptosis.

FLOT1 knockdown inhibits growth of AML cells through triggering apoptosis and pyroptosis.

Journal: Annals of hematology

Published: July 14, 2022

Dihydropyrimidinase-like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia.

Dihydropyrimidinase-like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia.

Journal: Cancer medicine

Published: July 04, 2022

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia.

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia.

Journal: Journal of translational medicine

Published: April 03, 2022

Characterization of the Newly Established Homoharringtonine- (HHT-) Resistant Cell Lines and Mechanisms of Resistance.

Characterization of the Newly Established Homoharringtonine- (HHT-) Resistant Cell Lines and Mechanisms of Resistance.

Journal: Journal of oncology

Published: February 20, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026